Plasma exchange may be doing more harm than good for people with atypical hemolytic uremic syndrome (aHUS), a small…
Articles by Marta Figueiredo, PhD
C5a, a terminal product of the complement system, can, by itself, promote blood vessel dysfunction and the subsequent formation of…
Some COVID-19 patients may develop severe atypical hemolytic uremic syndrome (aHUS), but it can be completely or partly resolved…
Endothelial cells, or those that line blood vessels, are functionally abnormal in people with atypical hemolytic uremic syndrome (aHUS)…
Two Phase 3 clinical trials will evaluate the safety and effectiveness of Roche’s investigational, self-injectable therapy crovalimab (RG6107) in…
A newly identified mutation in the C3 gene that causes severe, life-threatening atypical hemolytic uremic syndrome (aHUS) was found…
Researchers have reported a rare case of atypical hemolytic uremic syndrome (aHUS) in a 21-year-old Swiss-Indonesian man with lipoprotein…
Alexion Pharmaceuticals’ long-acting Ultomiris (ravulizumab) was added to the list of medications available through England’s national health service (NHS) to…
Ultomiris (ravulizumab) has been approved in Scotland for adults and children weighing at least 10 kg, or 22 lbs,…
People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of…